Cough in Patients With Lung Cancer Amélie S.M. Harle, PhD, Fiona H. Blackhall, PhD, Alex Molassiotis, PhD, Janelle Yorke, PhD, Rachel Dockry, PhD, Kimberley J. Holt, MPhil, Danielle Yuill, MRes, Katie Baker, PhD, Jaclyn A. Smith, PhD  CHEST  Volume 155, Issue 1, Pages 103-113 (January 2019) DOI: 10.1016/j.chest.2018.10.003 Copyright © 2018 American College of Chest Physicians Terms and Conditions

Figure 1 Recruitment process. ACM = ambulatory cough monitoring; BRI = Brief Reflux Inventory (patient reported); CSD = cough severity diary (patient reported); CTCAE = Common Terminology for Adverse Events cough severity grading scale (physician reported); EORTC QLQ C30+LC13 = European Organisation for Research and Treatment of Cancer Quality of Life Core 30 questionnaire and lung cancer LC13 module (patient reported); FU = follow-up; MCLC = Manchester Cough in Lung Cancer Scale (patient reported); VAS = cough severity visual analog scale (patient reported). CHEST 2019 155, 103-113DOI: (10.1016/j.chest.2018.10.003) Copyright © 2018 American College of Chest Physicians Terms and Conditions

Figure 2 A-F, Change in cough scores over time. A, Cough frequency was assessed using an objective ambulatory cough monitoring at study entry (day 0) and at day 60. Data are expressed as c/h over a 24-h time period. B, Patient responses to Q31 on the EORTC LC13, which asks patients to rate how much they coughed during the last week. Patient responses were recorded at study entry (day 0) and at day 60 based on the highlighted categories. Response data are expressed as percentage of overall study population (day 0: n = 173; day 60: n = 150). C, Cough severity was assessed using cough severity VAS scores at study entry (day 0), day 30, and day 60. Data are expressed as millimeter scores given by patients. Box plots are shown to demonstrate the medians scores given in addition to the interquartile and overall ranges of the data. D, Cough grading according to Common Terminology for Adverse Events cough severity grading scale assessed at study entry (day 0), day 30, and day 60. (Grade 1 was defined as mild symptoms, nonprescription intervention indicated. Grade 2 was defined as moderate symptoms, medical intervention indicated; limiting instrumental activities of daily living [ADL]. Grade 3 was defined as severe symptoms, limiting self-care ADL.) Data are expressed as percentage of overall study population (day 0: n = 176; day 30: n = 133; day 60: n = 139). E, Cough severity diary scores for patients at study entry (day 0) and day 60. Data are expressed as median score at the time points indicated. F, MCLCS cough impact score for patients at study entry (day 0), day 30, and day 60. Data are expressed as median score at the time points indicated. c/h = number of coughs per hour; EORTC LC13 = European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Lung Cancer 13; MCLCS = Manchester Cough in Lung Cancer Scale; Q31 = question 31. See Figure 1 legend for expansion of other abbreviations. CHEST 2019 155, 103-113DOI: (10.1016/j.chest.2018.10.003) Copyright © 2018 American College of Chest Physicians Terms and Conditions